Rebound of COVID 7 days after treatment Bad taste in mouth throughout treatment; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Rebound of COVID 7 days after treatment Bad taste in mouth throughout treatment) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Allergy (Allergy was reported to unknown past drug).   On 11-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (Rebound of COVID 7 days after treatment Bad taste in mouth throughout treatment). At the time of the report, COVID-19 (Rebound of COVID 7 days after treatment Bad taste in mouth throughout treatment) had not resolved. Not Provided          No concomitant medications were reported. The patient did not take any other medications/products within two weeks of starting COVID-19 treatment. On 14-May-2022, the patient experienced rebound of COVID 7 days after treatment, Bad taste in mouth throughout treatment.  Company Comment: This spontaneous case concerns a 46 year old male patient with no relevant medical history reported, who was treated with with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 03-May-2022 to 07-May-2022 for COVID-19 treatment, who experienced Non-serious , unexpected, AESI  of Covid 19 which occurred on an unknown date post vaccination with the 3rd dose of mRNA-1273 vaccine. Information regarding the dose 1 and dose 2  Covid 19 vaccine of this patient was not reported.  It was also reported that after treatment with Paxlovid there was rebound of Covid 19 seven  days after treatment described as bad taste in mouth throughout treatment.  Other treatment details , results of laboratories/diagnostic procedures like RT-PCR/ viral culture  were not reported and there was no report if any medical consult was done. Outcome of the event was reported as not resolved. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report; Sender's Comments: This spontaneous case concerns a 46 year old male patient with no relevant medical history reported, who was treated with with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 03-May-2022 to 07-May-2022 for COVID-19 treatment, who experienced Non-serious , unexpected, AESI  of Covid 19 which occurred on an unknown date post vaccination with the 3rd dose of mRNA-1273 vaccine. Information regarding the dose 1 and dose 2 Covid 19 vaccine of this patient was not reported.  It was also reported that after treatrment with Paxlovid there was rebound of Covid 19 seven  days after treatment described as bad taste in mouth throughout treatment.  Other treatment details , results of laboratories/diagnostic procedures like RT-PCR/ viral culture  were not reported and there was no report if any medical consult was done. Outcome of the event was reported as not resolved. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report